6th Annual MarketsandMarkets Next-Gen Bioprocessing Conference

6th - 7th October 2022 | London
CONFERENCE SPEAKERS
Advisors
Zhimei Du
Zhimei Du
Vice President - Allogeneic Cell Therapy,
Atara Biotherapeutics


. Zhimei graduated from Cornell University Medical College – Memorial Sloan Kettering Cancer Center Joint Immunology Program. After graduation, she joined Robert G. Roeder’s laboratory at The Rockefeller University, exploring the genetic/epigenetic regulation mechanisms during leukemia genesis. She started her industrial career at Regeneron as protein engineer for bi-specific antibodies. Later, she joined Amgen followed by Teva Pharmaceuticals focusing on bioprocess development of biotherapeutics manufacturing. Zhimei had extensive experience in cell/gene therapy. She led cell/gene therapy clinical programs for type I diabetes at Diabetes Research Institute, U. of Miami. Zhimei joined Merck & Co. where she served as the Executive Director & Global Head of Process Cell Sciences, leading Process Cell Sciences Department, including allogeneic CAR-T and CAR-NK cell therapy process development, cell line development, cell banking, genetic/cytogenetic characterization, biomarker and predictive modeling. Currently, Zhimei is the VP of Process Sciences at Atara Bio, a leading Allogeneic Cell/gene therapy company. Zhimei is also the sponsor and core member of multiple Industrial-wide Consortium teams, setting up road map and establishing industrial common practices in various biotherapeutics development areas, including ISPE ATMP, Allogeneic Accelerated Development Network, BioPhorum Cell/Gene therapy, ADC/Bispeicifics Roadmap team co-lead at BPOD/NIMBLE, IQ comparability team, IQ sequence variant consortium team, IQ Design Space team.


Dimitrios A. Lamprou
Dimitrios A. Lamprou
Director of MSc Industrial Pharmaceutics,
Queen's University Belfast


Dimitrios Lamprou (Ph.D. MBA) is Professor & Programme MSc Director at the School of Pharmacy, Queen's University Belfast (UK). Is also the Chair at United Kingdom and Ireland Controlled Release Society (UKICRS) and the Chair of the Academy of Pharmaceutical Sciences (APS) Emerging Technologies Focus Group. Dimitrios, is the author of over 120 peer-reviewed publications, has over 300 conference abstracts, has given over 120 Invited Talks in institutions and conferences across the world, and has secure Funding in excess of £2.5M. His research and academic leadership have been recognised in a range of awards, including the Royal Pharmaceutical Society Science Award and the Scottish Universities Life Sciences Alliance Leaders Scheme Award. Dimitrios expertise is in Emerging Biopharmaceutical & Pharmaceutical Technologies in the manufacturing of Drug Delivery Systems & Medical Implants.


Speakers
Anthony Colenburg
Anthony Colenburg
Director of Quality,
Adicet Bio, Inc



Zhimei Du
Zhimei Du
Vice President - Allogeneic Cell Therapy,
Atara Biotherapeutics


. Zhimei graduated from Cornell University Medical College – Memorial Sloan Kettering Cancer Center Joint Immunology Program. After graduation, she joined Robert G. Roeder’s laboratory at The Rockefeller University, exploring the genetic/epigenetic regulation mechanisms during leukemia genesis. She started her industrial career at Regeneron as protein engineer for bi-specific antibodies. Later, she joined Amgen followed by Teva Pharmaceuticals focusing on bioprocess development of biotherapeutics manufacturing. Zhimei had extensive experience in cell/gene therapy. She led cell/gene therapy clinical programs for type I diabetes at Diabetes Research Institute, U. of Miami. Zhimei joined Merck & Co. where she served as the Executive Director & Global Head of Process Cell Sciences, leading Process Cell Sciences Department, including allogeneic CAR-T and CAR-NK cell therapy process development, cell line development, cell banking, genetic/cytogenetic characterization, biomarker and predictive modeling. Currently, Zhimei is the VP of Process Sciences at Atara Bio, a leading Allogeneic Cell/gene therapy company. Zhimei is also the sponsor and core member of multiple Industrial-wide Consortium teams, setting up road map and establishing industrial common practices in various biotherapeutics development areas, including ISPE ATMP, Allogeneic Accelerated Development Network, BioPhorum Cell/Gene therapy, ADC/Bispeicifics Roadmap team co-lead at BPOD/NIMBLE, IQ comparability team, IQ sequence variant consortium team, IQ Design Space team.


Ioanna Tzani
Ioanna Tzani
Postdoctoral Researcher,
The National Institute for Bioprocessing Research and Training


Ioanna Tzani received her doctorate degree from University College Cork in 2017, where she studied protein synthesis regulation in cancer and identified previously uncharacterised proteoforms in the commonly mutated tumour suppressor PTEN. Since 2017 she is a member of Dr Colin Clarke’s Systems Biology group in the National Institute for Bioprocessing Research and Training (NIBRT, Dublin). In her current role she studies the effect of cell culture conditions on gene expression and protein synthesis through the application of both bulk and single cell -omics methods, aiming towards improving bioprocessing efficiency and quality and safety of recombinant therapeutic proteins. Her research interests include the application of molecular biology and -omics methods towards improving the production efficiency of advanced therapy medicinal products


Dimitrios A. Lamprou
Dimitrios A. Lamprou
Director of MSc Industrial Pharmaceutics,
Queen's University Belfast


Dimitrios Lamprou (Ph.D. MBA) is Professor & Programme MSc Director at the School of Pharmacy, Queen's University Belfast (UK). Is also the Chair at United Kingdom and Ireland Controlled Release Society (UKICRS) and the Chair of the Academy of Pharmaceutical Sciences (APS) Emerging Technologies Focus Group. Dimitrios, is the author of over 120 peer-reviewed publications, has over 300 conference abstracts, has given over 120 Invited Talks in institutions and conferences across the world, and has secure Funding in excess of £2.5M. His research and academic leadership have been recognised in a range of awards, including the Royal Pharmaceutical Society Science Award and the Scottish Universities Life Sciences Alliance Leaders Scheme Award. Dimitrios expertise is in Emerging Biopharmaceutical & Pharmaceutical Technologies in the manufacturing of Drug Delivery Systems & Medical Implants.


Christian Witz
Christian Witz
Senior Scientist,
Research Center Pharmaceutical Engineering GmbH



Paula Meleady
Paula Meleady
Associate Director,
National Institute for Cellular Biotechnology



Nidhi Gautam
Nidhi Gautam
Associate Director,
Astrazeneca



John Maher
John Maher
Leucid Bio,
Scientific Founder and Chief Scientific Officer


Dr John Maher is a clinical immunologist and immunopathologist who leads the "CAR Mechanics" research group within King's College London. He played a key role in the early development of  second generation CAR technology that has proven disruptive in the clinic. His research group is focused on the development of adoptive immunotherapy using CAR engineered and gamma delta T-cells. He is also the scientific founder and chief scientific officer of a spin-out company named Leucid Bio. In addition, he is a consultant immunologist within King's Health Partners and Eastbourne Hospital.


Oliver Spadiut
Oliver Spadiut
Associate Professor,
TU Wien



Cynthia N. Brysch
Cynthia N. Brysch
Principal Consultant,
Vertex Pharmaceuticals



Ohad Karneili
Ohad Karneili
Founder & CEO,
Adva Biotechnology


A well-known international expert in cell therapy with extensive knowledge of the industry. Dr Karnieli is the founder and CEO of Adva Biotechnology, a leading automation platform for cell and gene therapy. Dr Karnieli was the founder and former President of Atvio Biotech, a specialized cell and gene therapy innovation center which was sold to Orgenesis Inc. Former VP of Technology & Manufacturing at Pluristem Therapeutics, and the former VP medical device at Goji solutions. Dr Karnieli served as the chair of several industry committees such as the process & product development committee of the International Society for Cellular Therapies, expert member in the ISO TC276 Biotechnology standard committee and the former chair of the science and technology committee of the Alliance for Regenerative Medicine. Furthermore, Dr Karnieli serves as an advisor and board member to several of the lead cell therapy developing companies. Dr Karnieli earned his PhD on Cell and Gene Therapy in the Sackler School of Medicine of the Tel Aviv University. Furthermore, he holds an MBA from the Haifa University business management school.


Leonardo Rios Solis
Leonardo Rios Solis
Senior Lecturer (Assoc Prof),
The University of Newcastle



Carmen Brenner
Carmen Brenner
Director MSaT,
Novadip



Pedro Silva Couto
Pedro Silva Couto
Post-Doctoral Research Fellow,
University College London


Pedro Silva Couto is a post-doctoral research fellow at University College London (UCL). His role is part of a European consortium focused on CAR-T cell manufacturing named Artificial Intelligence-driven, Decentralized Production for Advanced Therapies in the Hospital (AIDPATH).

Pedro previously completed his PhD under the supervision of Dr. Qasim Rafiq at UCL. His work focused on the manufacturing of ex vivo gene therapy and extracellular vesicles using human mesenchymal stromal cells (hMSCs) for clinical applications. Pedro received a Master’s in Biochemical Engineering from IST, Portugal.  


Sonia Sahukar
Sonia Sahukar
Upstream development Scientist,
Alvotech



Matt Davis
Matt Davis
Director, Molecular biology and Sequencing,
Gritstone Oncology, Inc.


Matt Davis PhD joined Gritstone Oncology (NASDAQ: GRTS) in 2015 and is currently the Director of Molecular Biology and Sequencing responsible for various neo-antigen discovery and translational genomics efforts.  Prior to Gritstone, Dr. Davis conducted post-doctoral research at Warp Drive Bio in the discovery biology group.  He holds a PhD in Genetics from Yale with thesis research under the supervision of Dr. Joseph Schlessinger and previous to his graduate work he conducted cancer genomics research at Dana Farber Cancer Institute and the Broad Institute.